CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$51.78
+3.57%Year over year
Reported trailing growth
- Revenue
- -33.1%
- EBITDA
- +6.9%
- EBIT
- -10.8%
- EPS
- +15.2%
- Free cash flow
- -25.1%
- Operating cash flow
- -23.8%
Forward estimates
Based on analyst estimates
- Revenue
- +228.8%
- EBITDA
- +21.8%
- EPS
- +17.8%
Three-year CAGR
- Revenue
- +100.4%
- EBITDA
- -62.6%
- EBIT
- -21.8%
- Net income
- -58.8%
- EPS
- -49.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026